← Browse by Condition
Medical Condition

advanced malignancies

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for advanced malignancies sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — advanced malignancies Clinical Trials

How many clinical trials are currently recruiting for advanced malignancies?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for advanced malignancies, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for advanced malignancies?
advanced malignancies research spans Phase 1 (5 trials), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a advanced malignancies clinical trial?
Eligibility criteria for advanced malignancies trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
5
Phase 2
1
Top Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 1 trial
Innovent Biologics (Suzhou) Co. Ltd. 1 trial
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 1 trial
Beijing Mabworks Biotech Co., Ltd. 1 trial
Pfizer 1 trial

Recruiting Clinical Trials

NCT06717880 Phase 1
Recruiting
A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer
Enrollment
260 pts
Location
China
Sponsor
Union Hospital, Tongji Medical...
View Trial →
NCT06468098 Phase 1
Recruiting
A Study of IBI363 in Subjects With Advanced Malignancies
Enrollment
556 pts
Location
China
Sponsor
Innovent Biologics (Suzhou) Co...
View Trial →
NCT06202261 Phase 1, Phase 2
Recruiting
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Enrollment
154 pts
Location
China
Sponsor
Chia Tai Tianqing Pharmaceutic...
View Trial →
NCT04651348 Phase 1
Recruiting
A Clinical Study of MIL95 in Advanced Malignancies.
Enrollment
58 pts
Location
China
Sponsor
Beijing Mabworks Biotech Co., ...
View Trial →
NCT07426757 Phase 1
Recruiting
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
Enrollment
120 pts
Location
United States
Sponsor
Pfizer
View Trial →

Related Conditions

metastatic breast cancer (1) recurrent breast cancer (1) advanced cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology